KCT0007975招募中未知
Multicenter, randomized, pivotal clinical study to evaluate the efficacy and safety of low temperature microwave plasma technology with mild and moderate topical atopic dermatitis
Medipl0 个研究点目标入组 87 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 6(Year) 至 74(Year)（—）
- 性别
- All
入选标准
- •(1) Male or female, 6 to 74 years
- •(2) patients with a diagnosis of chronic atopic dermatitis based on Hannifin and Rajka criteria over 2years.
- •(3) patients who have atopic dermatitis lesions with total body surface area(BSA) >5% were included. IGA score 2(mild) or 3(moderate)
- •(4) patients who have atopic dermatitis with symmetric skin lesions.
- •(5) patients who agrees to contraception during the entire trial period
- •(6) patients who understand and comply with the procedure
- •(7) patients who are able to read, understand and voluntarily sign the ICF
排除标准
- •(1) Presence of severe skin diseases or large skin scars that may interfere with study assessments, per investigator judgment
- •(2) Patients with other medical(liver disease, renal failure, and others), psychotic and neurotic causes that may interfere with study assessments
- •(3) Patients with a history of topical steroids, Immunosuppressive/immunomodulating drugs or antibiotics for treatment of AD within 7 days of the screening visit
- •(4) At baseline, patients who are within 1 month of systemic therapy, 2 weeks of topical therapy, 2 months of biologics or 5 half-lives(if known), (whichever is longer)
- •(5) Patients who used steroids, antibiotics, immunosuppressive/immunomodulating drugs(systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-?, Janus kinase inhibitors, azathioprine, methotrexate, etc.) as a systemic drug treatment within 1 month before the screening visit.
- •(patients may continue using stable does of such systemic antihistamines if initiated before the screening visit. It is possible to reduce or stop the dose of the drug, but not increase the dose. )
- •(6) Treatment with TCS or TCI within 1 week before the baseline visit
- •(7) Treatment with an investigational drug within 1 month screening visit (if biologics, within 4 months or 5 half-lives, whichever is longer
- •(8) Treatment with a live (attenuated) vaccine within 3months before the baseline visit
- •(9) Treatment with biologics as follows
- •- Any cell-depleting agents : within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer
- •- Other biologics : within 5 half-lives(if known) or 4 weeks prior to baseline visit, whichever is longer
- •(10) At baseline, presence of any conditions listed as exclusion criteria
- •(11) Initiation of treatment of AD with prescription moisturizers or moisturizes containing additives such as hyaluronic acid, urea, or filaggrin degradation products during the screening period(patients may continue using stable doses of such moisturizers if initiated before the screening visit)
- •(12) Planned or anticipated use of any prohibited medications and procedures during study treatment
- •(13) Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. (patients may be rescreened after infection resolves)
- •(14) Planned or anticipated major surgical procedure during the patient’s participation in this study
- •(15) Pregnant or breastfeeding women, or who disagree with contraception until 4 weeks later from last treatment
- •(16) History of human immunodeficiency virus(HIV) infection/positive HIV serology or hepatitis B surface antigen (HBsAg)/hepatitis C antibody at screening
- •(17) History of malignancy within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin
- •(18) Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection, unless clinical and(if necessary) laboratory assessment have ruled out active infection before randomization
- •(19) Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, pose a significant risk to the participant; or in
研究者
相似试验
进行中（未招募）
不适用
A clinical trial of topiramate vs placebo for newborns with perinatal asficia body treated with hypothermia.EUCTR2011-005696-17-ESInstituto de Investigacion Sanitaria La Fe
进行中（未招募）
不适用
A multicentre, randomised, open clinical study to compare the efficacy and safety of a combination of tacrolimus with sirolimus versus tacrolimus with mycophenolate mofetil in kidney transplantatioEUCTR2004-000457-34-ITFUJISAWA
进行中（未招募）
不适用
An open, randomised, multicentre clinical study to uinvestigate the safety and efficacy of steroid withdrawal with tacrolimus, mychopenolate mofetil and daclizumab against tacrolimus, mychopenolate mofetil and steroids in children after kidney transplantation - TWIST-Tacrolimus and WIthdrawal of STeroidsEUCTR2005-001348-22-ITAstellas Pharma GmbH200
尚未招募
不适用
Multicenter, randomized, open clinical study to evaluate efficacy and safety of Calcineurin inhibitors versus Mycophenolate in pediatric steroid-resistant nephrotic syndromeKCT0007983Seoul National University Hospital140
进行中（未招募）
1 期
A study to assess the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including infective endocarditisComplicated staphylococcus aureus bacteremia (cSAB)MedDRA version: 20.1Level: LLTClassification code 10058887Term: Staphylococcus aureus bacteremiaSystem Organ Class: 100000004862EUCTR2017-001699-43-ESBasilea Pharmaceutica International Ltd390